Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleWang M, He Y, Hu H, et al., 2026, , Redox Rep, Vol: 31
BACKGROUND: Fatty acid oxidation (FAO) is implicated in lung diseases, but its role in bronchial asthma is not fully understood. We investigated its effect on airway epithelial barrier integrity. METHODS: Using a house dust mite (HDM)-induced murine asthma model and HDM, IL-4, IL-13, or TNF-α stimulated human primary bronchial epithelial cells (BECs) and bronchial epithelial (Beas-2b) cells, we modulated FAO with L-carnitine (agonist) and Etomoxir (inhibitor). BECs and Beas-2b cells were infected with lentivirus-mediated CPT1A shRNA prior to stimulation. Barrier function, mitochondrial oxidative stress, inflammation, and metabolism were assessed. RESULTS: FAO level in lungs negatively correlated with increased inflammation and tissue injury in HDM-induced asthmatic mice (all p < 0.05), while positively regulating tight junction protein expression. In BECs and Beas-2b cells, Etomoxir treatment and CPT1A knockdown exacerbated the impairment of FAO caused by various stimulants (all p < 0.05). Furthermore, FAO negatively regulated HDM/cytokine-induced epithelial barrier damage, hyperactive inflammatory response, and mitochondrial dysfunction in Beas-2b cells (all p < 0.05). In contrast, treatment with L-carnitine significantly alleviated these pathophysiological features in both in vivo and in vitro models. CONCLUSION: FAO plays a protective role in the occurrence and development of asthma by maintaining airway epithelial cell homeostasis and barrier function.
-
Journal articleLin Y, Mumby SE, Abubakar-Waziri H, et al., 2026, , J Lipid Res
Specialized pro-resolving mediators (SPMs) alleviate airway hyperresponsiveness, reduce eosinophil infiltration, and promote efferocytosis in allergic mouse models. Comparable human evidence, however, is limited. This study aims to define the relationship between nasal SPMs and respiratory outcomes. In a panel study of 26 adults with mild-to-moderate asthma (MMA) and 33 adults without asthma, we collected nasal fluid samples longitudinally up to 4 times on each participant for the analysis of 21 lipid mediators, to associate with measures of lung function, airway resistance, and fractional exhaled nitric oxide (FeNO). The same panel of lipid mediators was also measured in a subgroup of 15 paired bronchoalveolar lavage fluids (BALF) samples. Six SPMs (i.e., LXA4, LXB4, RvD2, RvD5, MaR1, and RvE4) were detected in nasal fluid, all of which were positively correlated with PGE2, 5- and 12/15-lipoxygenase (LOX) metabolites. In MMA participants, levels of RvD5, 12/15-LOX metabolites and PGE2 were lower. Atopy status, history of rhinitis, and medication use was not associated with changes in SPMs. However, the use of inhaled corticosteroids was associated with decreased levels of PGE2, a mediator known to trigger the lipid class switch from pro-inflammatory to pro-resolving responses. Higher RvD2 and RvD5 levels were associated with higher lung function while higher RvD2 levels were also associated with lower FeNO. RvD5 levels in nasal fluid were moderately correlated with those in BALF (Spearman r= 0.48, p=0.07). Our results indicate that nasal SPMs were lower in asthmatic individuals and were associated with higher lung function and lower airway inflammation.
-
Journal articleAdcock IM, 2026, , Br J Pharmacol
There have been several step-changes in asthma therapy, with the first being the use of inhaled short-acting β2-agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long-acting bronchodilators together with inhaled corticosteroids in the same inhalation device for improved asthma control. The most recent step-change is the introduction of targeted monoclonal antibodies in patients with severe asthma and frequent exacerbations with biomarkers reflecting high levels of Type 2 (T2) inflammation. In chronic obstructive pulmonary disease (COPD), advances in bronchodilator therapy have been made, but limited advances in treating the inflammation and lung remodelling changes are present. We need new therapeutic agents for patients with a sub-optimal response to current drugs. The aim of this narrative review is to provide a summary of the potential future anti-inflammatory approaches undergoing testing for asthma and COPD rather than provide a systematic review. These approaches aim to optimize current treatment regimens and to develop novel agents against differing aspects of asthma and COPD pathophysiology. However, clinical trial results highlight our limited understanding of the biology of asthma and COPD subtypes. Furthermore, failed studies provide insight into disease pathophysiology and may indicate responder/non-responder populations. Various aspects of cytokine- and environment-activated intracellular pathways are being targeted. These include receptor agonists and antagonists and inhibitors of the Janus kinase (JAK) and Bruton tyrosine kinase (BTK) pathways for use against both stable disease and for reducing disease exacerbations or 'attacks'. New or better use of current biomarkers will provide non-invasive means of patients most likely to respond to any one specific or combination of drugs.
-
Journal articleHopkinson N, 2026,
The ethics of tobacco control -"good people doing good things"
, Tobacco Control, ISSN: 0964-4563A richer understanding of the ethical basis for ending the tobacco epidemic has the potential to strengthen the case for change. This paper first addresses the way that the two key moral goods of wellbeing and freedom, elements of a “good life”, are limited by tobacco dependence. The limited negative view of freedom as a lack of prohibition is rejected in favour of a view of freedom as capability – what individuals can actually do. Second, arguments around tobacco control are considered through the long-established medical ethics framework of Principlism – an approach that weighs decisions according to their respect for beneficence, non-maleficence, autonomy, and distributive justice. The ethical responsibilities of healthcare and other organisations, as well as government are considered. As are the ethics of the tobacco industry itself, whose products drastically limit human wellbeing and freedom, yet uses moral arguments to promote itself through corporate social responsibility, are considered.The enormous impact of smoking on both wellbeing and freedom, combined with the existence of effective means to end these harms, provides a moral imperative to pursue the Tobacco Endgame.
-
Journal articleAlferes de Lima Headley D, Richardson H, Hennayake C, et al., 2026, , Eur Respir J, Vol: 68
BACKGROUND: Acute COVID-19 alters the airway microbiota. Whether these changes persist post-COVID-19 and contribute to long COVID is unknown. We aimed to describe the microbiota by long COVID severity and subtype, and identify links with inflammation. METHODS: Adults were prospectively recruited to the longitudinal UK Post-hospitalisation COVID-19 study (PHOSP-COVID). Patients were grouped by previously described "severity clusters" (of ongoing health impairments) and symptom subgroups. Oral and sputum microbiota (at 6鈥卪onths post-discharge) were characterised through 16S ribosomal RNA gene amplicon sequencing, and microbiota diversity was assessed. Co-occurrence network analysis identified keystone taxa. Associations between keystone taxa and plasma inflammatory proteins were assessed through Spearman's rank correlations. RESULTS: 771 participants had their microbiota assessed. Of participants with oral rinses and "severity cluster" assignment (mean age 57.5鈥厃ears), 278 out of 722 (38.5%) were women. The "very severe" cluster, in which disease was predominantly pulmonary in nature, was associated with a distinct microbiota profile post-COVID-19. Reduced lung function was associated with a distinct oral microbiota profile. Persistent neurocognitive symptoms were associated with a distinct oral microbiota profile, while gastrointestinal symptoms were associated with a distinct sputum microbiota profile. Microbiota keystone taxa shifted to a higher prevalence of lactic acid bacteria associated with worse health outcomes. Lactic acid bacteria abundance was associated with elevated blood inflammatory proteins. CONCLUSION: Distinct oral and sputum microbiota profiles were associated with pulmonary function and with neurocognitive and gastrointestinal symptoms in long COVID. Shifts in keystone microbiota taxa linked with inflammation, based on worse health outcomes, suggest a potential role change for lactic acid bacteria, which may be associ
-
Journal articleGalant SP, Karp T, Kuks PJM, et al., 2026, , J Allergy Clin Immunol Pract, Vol: 14, Pages: 2714-2717.e2
-
Journal articleAnastasiou E, Mathioudakis AG, Adachi Y, et al., 2026, , Pediatr Allergy Immunol, Vol: 37
BACKGROUND: Achieving and maintaining pediatric asthma control depends on effective and regular monitoring. While a wide range of monitoring tools are available, how and why clinicians use these in routine practice has not been formally characterized. Here we describe distinct real-world monitoring patterns among healthcare professionals (HCPs) caring for children with asthma in an international convenience survey, examining the geographic, professional, and institutional factors associated with them. METHODS: Data from the international cross-sectional Pediatric Asthma in Real Life (PeARL) HCP survey, administered to clinicians with expertise in childhood asthma, were analyzed. Monitoring patterns were derived by Ward agglomerative hierarchical clustering on four standardized domains: clinical evaluation, spirometry, fractional exhaled nitric oxide (FeNO), and home-monitoring. Independent associations between cluster membership and region, specialty, sector, and level of care were estimated by multinomial logistic regression (MLR). RESULTS: 951 HCPs from 78 countries were included. Four monitoring patterns emerged: Low-intensity (n = 88, 9.3%), lower overall monitoring intensity but moderate clinical assessment; Clinical (n = 449, 47.2%), predominantly clinical assessment with moderate spirometry but infrequent FeNO and home monitoring; Clinical & Objective (n = 308, 32.4%) with additional regular spirometry with moderate FeNO use and Comprehensive (n = 106, 11.1%), also providing home monitoring. In MLR (n = 933), region and care level were significantly associated with cluster membership (p < .001), and specialty (p = .012) and sector (p = .039) also contributed independently. The most pronounced gradients involved objective in-clinic testing: specialists were 3.5-fold (95% CI 1.68-7.37) more likely than generalists, and tertiary-care HCPs 3.3-fo
-
Journal articleVan Vaerenbergh F, Vauterin D, Bloom C, et al., 2026, , ERJ Open Res, Vol: 12, ISSN: 2312-0541
BACKGROUND: Prior research has focused on short-acting β2-agonist (SABA) overuse-related adverse outcomes in asthma patients. Evidence on the association between use of short-acting bronchodilators in general and cardiovascular events in asthma/COPD populations remains limited. METHODS: Adult patients with chronic treatment of asthma or COPD were identified in a Belgian nationwide cohort between 2017 and 2022. A Cox model adjusted for age, sex, smoking, socioeconomic status, exacerbation history, comorbidities and medication use, was used to investigate the association between SABA, short-acting muscarinic antagonist (SAMA) and SABA+SAMA use with cardiovascular risk and all-cause mortality. RESULTS: The cohort included 226 314 asthma patients (mean age 57.8 years, 60.5% females) and 57 446 COPD patients (mean age 72.2 years, 38.0% females). Compared with no use, SAMA and SABA+SAMA use (1-2 and ≥3 canisters per baseline year) was associated with increased heart failure (1.2-1.4-fold), arrhythmia (1.1-1.4-fold) and mortality risk (1.1-1.7-fold) in asthma and COPD patients. Among asthma patients, use of 1-2, and ≥3 SABA+SAMA canisters per year were additionally associated with increased myocardial infarction (1.2-1.4-fold) and ischaemic stroke risk (1.2-1.3-fold), and ≥3 SABA+SAMA canisters per year with a 1.4-fold myocardial infarction risk in COPD patients. Compared with no SABA users, ≥3 SABA canisters per year was associated with a 1.1-fold increased heart failure and mortality risk in asthma and COPD patients, while no increased risks were observed for 1-2 SABA canisters. CONCLUSION: Increased use of SAMA or SABA+SAMA was associated with increased risks of cardiovascular events and mortality in patients with asthma and COPD. Collecting three or more SABA canisters per year was associated with increased mortality.
-
Journal articleChen R-C, Xiao D, Kang J, et al., 2026, , Lancet Respir Med
For the Chinese translation of the abstract see Supplementary Materials section.
-
Journal articleWalsh SLF, Maher TM, Kolb M, et al., 2026, , Eur Respir J
-
Journal articleTorres MJ, Canonica GW, Giavina-Bianchi P, et al., 2026, , Allergy
-
Journal articleJee AS, Pugashetti JV, Yazbeck L, et al., 2026, , Eur Respir J
Application of the 2015 Interstitial Pneumonia with Autoimmune Features (IPAF) research statement produced IPAF cohorts with favorable transplant-free survival (TFS) relative to the idiopathic interstitial pneumonia (IP) base populations from which they arose. Whether differences in underlying fibrotic morphology may explain this observation remains unclear.A multi-centre retrospective cohort study was performed. IPAF criteria were applied to six idiopathic IP cohorts from the US and UK using available clinical data. Fibrotic morphology was determined in separate analyses using imaging and histopathological data. Three-year TFS was compared between cohorts before and after adjustment for fibrotic morphology. Stratified analyses were performed to assess the prognostic significance of IPAF classification and presence clinical and serological domain features within key morphological groups. Outcomes were benchmarked against a connective tissue disease-associated (CTD-ILD) reference cohort (n=1566).Of 5042 individuals with idiopathic IP included in the analysis, 649 (12.9%) met IPAF criteria. Whilst IPAF classification was associated with favorable TFS before adjustment for imaging-based fibrotic morphology (HR 0.79; 95% CI 0.68-0.92; p=0.003), this association was attenuated after adjustment (HR 0.91; 95% CI 0.77-1.07; p=0.25). Results were similar when adjusting for histopathological-based morphology. IPAF classification had no prognostic significance within common morphological groups, but the presence of IPAF clinical domain features captured a phenotype with CTD-ILD-like natural history in the setting of non-UIP morphology.After accounting for differences in fibrotic morphology, IPAF classification has no prognostic significance relative to the idiopathic IP base population, suggesting that the current IPAF construct may not effectively identify a unique population.
-
Journal articleWorm M, D枚lle-Bierke S, Pouessel G, et al., 2026, , Clin Exp Allergy
BACKGROUND: The role of cofactors contributing to anaphylaxis severity remains unclear. METHODS: We analysed data from the European Anaphylaxis Registry (2007-2024) to determine the impact of suspected cofactors on reaction severity. Adjusted odds ratios (aOR) were calculated for the number of organ systems affected, but also two severity classification systems (Ring/Messmer and Brown). RESULTS: At least one suspected cofactor was reported in 8310 cases (49%) out of 16,915. Cofactors were less frequently suspected among younger patients (< 18 years: 26% and ≥ 18 years: 59%). Medication was the most common suspected cofactor in adults (41%), followed by exercise (27%), which was in parallel the most frequent suspected cofactor in children (19%). Emotional burden (children 3%/adults 8%), alcohol (0.4%/8%), sleep deprivation (0.5%/2%) and menstruation (2%/4%) were less commonly reported. We observed a trend between reaction severity and an increasing number of suspected cofactors. Among suspected cofactors, we observed consistent effects on anaphylaxis reaction severity for acute infections among children and alcohol consumption among adults in food-induced reactions. Moreover, we identified an association between the presence of a suspected cofactor(s) and an increased time interval between exposure and onset of symptoms across all age groups in food-induced anaphylaxis. CONCLUSIONS: Our data suggest an age-dependent role of suspected cofactors in anaphylaxis severity. Clinicians should explore the presence of cofactors in patients who experienced anaphylaxis, in particular in those with prolonged time intervals between exposure and reaction onset.
-
Journal articleDevulder J, 2026, , ERJ Open Research, ISSN: 2312-0541
-
Journal articleLu Y-T, John AE, Fern谩ndez-Yag眉e MA, 2026, , Adv Mater
Cells and extracellular matrices (ECMs) form mechanically coupled feedback loops in which cells generate forces, remodel their surroundings, and respond to mechanical information returned by the matrix. Conventional biomaterial models have established how passive matrix properties, including stiffness, viscoelasticity, architecture, and ligand presentation, regulate this feedback, but they provide limited control over the dynamic mechanical inputs transmitted through living tissues. Mechanoactive biomaterials address this limitation by converting external or encoded triggers into mechanical inputs with defined timing, magnitude, frequency, and spatial localization. Here, we compare mechanochemical hydrogels, light-responsive matrices, thermoresponsive systems, and optothermal mechanoactuators according to the material response, the mechanical input experienced by cells, spatial, and temporal control, reversibility, cytocompatibility, quantification, and translational constraints. We discuss how these platforms engage integrin-focal adhesion signaling, mechanosensitive ion channels, cytoskeletal and nuclear mechanotransduction, YAP/TAZ activity, and TGF-β activation. We conclude with design principles for selecting reversible or persistent actuation, matching mechanical parameters to receptor and tissue mechanics, and advancing mechanoactive platforms toward predictive in vitro models.
-
Journal articleZakari A, Chen Y-H, Chen P-J, et al., 2026, , J Hazard Mater, Vol: 518
Ambient air pollution has detrimental effects on human health. We investigated exposure-related differences and microbial overlap among PM鈧�, lung, and gut microbiomes in mice exposed to PM鈧�, high-efficiency particulate air (HEPA)-filtered air, or clean air. PM鈧� was characterized for soluble ions, metals, carbonaceous fractions, and oxidative potential, while gaseous pollutants data were obtained from air-quality monitoring stations. PM鈧�, lung, and gut microbiomes were analyzed using 16S rRNA sequencing, and short-chain fatty acids (SCFAs) were quantified by gas chromatography-mass spectrometry (GC-MS). Proteobacteria was the dominant phylum in PM鈧�. PM鈧� contained diverse chemical constituents, including soluble ions, metals, and oxidative species. Lung microbial diversity remained largely unchanged, whereas the gut microbiome was significantly altered. Compared with control, the PM鈧� group showed reduced Actinobacteriota and Bacteroidota, while Campylobacterota and Patescibacteria decreased in both HEPA and PM鈧� groups. Verrucomicrobiota increased in the HEPA group, and Proteobacteria increased in the PM鈧� group compared with both HEPA and control groups. Correlation analyses identified associations between lung and gut microbiomes, environmental variables, PM鈧� characteristics, gaseous pollutants, and SCFAs. Eleven bacterial families and six genera overlapped among PM鈧�, lung, and gut microbiomes in the PM鈧� group. Overall, ambient air pollution was associated with gut dysbiosis in mice.
-
Journal articleKarp T, Faiz A, Kerstjens HAM, et al., 2026, , J Allergy Clin Immunol
INTRODUCTION: Environmental seasonal changes, including allergen exposure, pollutants, and viral prevalence, impact gene expression across human tissues. Therefore, season of sample collection is critical to consider when analyzing disease-associated transcriptional programs. In this study we aimed to investigate the effect of season on identification of asthma-associated genes. METHODS: We analyzed RNA-seq data from nasal brushes of asthma patients (n=361) and healthy controls (n=57) included in the ATLANTIS study. Samples were compared across two time periods defined by a data-driven approach: winter-spring (Nov 15 -May 14) and summer-autumn (May 15 - Nov 14), correcting for age, sex, smoking, and asthma status. Gene Set Variation Analysis (GSVA) scores of the obtained seasonal gene signatures were compared using Mann-Whitney U test in the independent PIAMA cohort (n=325) for replication. RESULTS: We identified 1,731 genes differentially expressed between the two time periods (813 higher and 918 lower in winter-spring compared with summer-autumn; FDR < 0.05). This signature was replicated in the PIAMA cohort nasal gene expression data and was independent of asthma or allergy status. Samples collected in winter-spring showed a significantly lower predicted proportion of ciliated cells (p = 0.005) and a higher proportion of basal cells (p = 0.04) compared to those from summer-autumn. Crucially, including season as a covariate in models for asthma-associated gene expression nearly doubled the number of differentially expressed genes, from 126 to 271 (FDR < 0.05). We conclude that season of sampling strongly affects the nasal transcriptome, and we demonstrate that season-adjusted analyses significantly enhance sensitivity for detecting disease-associated changes.
-
Journal articleHolaman J, Sills D, Saumtally H, et al., 2026, , J Cyst Fibros
BACKGROUND: Gastrointestinal symptoms remain common in adults with cystic fibrosis (CF) despite cystic fibrosis transmembrane conductance regulator modulator use, suggesting persistent and heterogeneous gut dysfunction. This prospective observational study tests the hypothesis that distinct gut symptom phenotypes in CF can be observed and linked to underlying mechanisms. METHODS: Adults from three UK CF centres completed the Gastrointestinal Symptom Rating Scale, Patient Assessment of Constipation Symptoms and a bowel-habit questionnaire. Latent class analysis using an ordinal logistic model was applied to 36 symptom indicators. Associations between phenotypes and demographic, clinical, and treatment variables were examined using generalised linear models. RESULTS: Three hundred participants completed questionnaires (54% male; median 31 years). We identified four symptom phenotypes: mild; moderate-constipation predominant; moderate-diarrhoea predominant and severe. The severe phenotype was associated with gastroesophageal reflux (RRR 2.86; 95%CI: 1.30-6.31; p = 0.009), distal intestinal obstruction syndrome (RRR 2.46; 95%CI: 1.04-5.81; p = 0.04), proton pump inhibitor (RRR 3.29; 95%CI 1.39-7.74; p = 0.007), and laxative use (RRR 6.13; 95%CI 2.54-14.84; p < 0.001). CF-related liver disease was associated with both moderate-constipation and diarrhoea phenotypes, respectively (RRR 2.08; 95%CI 1.13-3.81; p = 0.018; RRR 2.11; 95%CI 1.03-4.29; p = 0.04). There was a lower likelihood of long-term oral antibiotic use in the moderate-constipation phenotype (RRR 0.53; 95%CI 0.3-0.92; p = 0.025) and moderate-diarrhoea phenotype (RRR 0.46; 95%CI 0.24-0.91; p = 0.025). CONCLUSIONS: Four distinct symptom phenotypes were identified, independent of demographics and pancreatic status, but associated with specific complications and medication profiles. These phenotypes provide a framework for mechanistic studies within the GRAMPUS-CF cohort and precision management of CF-related g
-
Journal articleMcKee M, Greenhalgh T, Hopkinson NS, 2026, , BMJ, Vol: 395
-
Journal articlePan Z, Du Z, Layhadi JA, et al., 2026, , Allergy
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.